Sacituzumab Govitecan is a type of treatment used in this clinical trial for patients with a specific kind of cancer called urothelial cancer, which affects the urinary system. This medication is designed to target and attach to cancer cells, delivering a powerful drug directly to them. The goal is to help shrink the tumors or slow down their growth, making it easier to manage the disease. This treatment is particularly used when the cancer is advanced and cannot be removed by surgery. By focusing on the cancer cells, it aims to reduce the impact on healthy cells, potentially leading to fewer side effects compared to traditional chemotherapy. This trial is exploring how effective this medication is in improving the condition of patients with this type of cancer.

Locally Advanced/Metastatic Urothelial Cancer – This is a type of cancer that originates in the urothelial cells lining the bladder and can spread to nearby tissues or distant organs. In its locally advanced stage, the cancer has grown into nearby tissues or lymph nodes but has not spread to distant parts of the body. When it becomes metastatic, the cancer cells have spread to other parts of the body, such as the liver, lungs, or bones. The disease progresses as cancer cells continue to grow and invade other tissues, potentially leading to the formation of new tumors in different locations. The progression can vary greatly among individuals, with some experiencing rapid spread while others may have slower disease advancement. The symptoms and impact on the body depend on the extent and location of the cancer spread.